Merck News (NYSE:MRK)

DateTimeSource
Headline
12/06/20168:20AMBWUpdated KEYTRUDA® (pembrolizumab) Data in Small Cell Lung Cancer & Mesothelioma Presented at 17th World Conference on Lung C...
Findings in Small Cell Lung Cancer and Malignant Pleural Mesothelioma Show Overall Response Rates of 33.3 Percent and 20.0 Percent, Respectively, in KEYNOTE-028 Long-Term Data Demonstrate Durable Responses in Difficult-to-Treat Cancers Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced... More...>>
12/06/20168:00AMBWMerck to Participate at the Citi 2016 Global Healthcare Conference
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Dr. Roger M. Perlmutter, president, Merck Research Laboratories, is scheduled to participate at the Citi 2016 Global Healthcare Conference in New York on Dec. 7, 2016 at 12:35 p.m. EST. Investors, analysts, members of the media and... More...>>
12/06/20162:50AMDJNU.S. 'Disappointed' by Japan's Plan to Cut Drug Costs
TOKYO—The U.S. government has written to a senior aide of Japan's Prime Minister Shinzo Abe, calling on Tokyo to reconsider a plan that would allow more frequent pharmaceutical price cuts. The letter from Secretary of Commerce Penny Pritzker describes how the U.S. is "disappointed" by the Japanese... More...>>
12/05/20167:30PMBWKEYTRUDA® (pembrolizumab) Treatment Results in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) Present...
Data from Pivotal KEYNOTE-087 Trial Show Overall Response Rate (ORR) of 69.0 Percent and Complete Remission Rate (CRR) of 22.4 Percent With More than Two Years of Follow-up, Findings from KEYNOTE-013 Show ORR of 58 Percent and CRR of 19 Percent with Responses of 12 Months or Greater in 70 Percent of Responding Patients... More...>>
12/05/201610:42AMBWUpdated KEYTRUDA® (pembrolizumab) Findings in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma...
Data from KEYNOTE-013 Demonstrated Overall Response Rate of 41 Percent, with 86 Percent of Responses Ongoing at the Time of Analysis Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today study findings demonstrating that KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, achieved... More...>>
12/01/20167:00AMBWFDA Grants Priority Review to Supplemental Biologics License Application (sBLA) for Merck’s KEYTRUDA® (pembrolizumab) in R...
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of patients with refractory... More...>>
11/30/20167:00AMBWNew KEYTRUDA® (pembrolizumab) Data to be Presented at 17th World Conference on Lung Cancer Highlight Research Across the Spe...
Findings to be Presented in Non-Small Cell Lung Cancer, Small Cell Lung Cancer and Malignant Pleural Mesothelioma with KEYTRUDA as Monotherapy and in Combination with Other Treatments Quality of Life Data from KEYNOTE-024 in First-Line Non-Small Cell Lung Cancer to be Presented in Plenary Session Merck (NYSE:MRK), known... More...>>
11/29/20167:00AMBWActress Bellamy Young, Merck, and Leading Lung Cancer Advocates Urge Those Impacted by Lung Cancer to Test. Talk. Take Action.
Young to Help Educate on the Importance of Biomarker Testing in Non-Small Cell Lung Cancer Acclaimed actress and singer Bellamy Young lost her father to lung cancer, and she is now sharing her personal experience as part of Test. Talk. Take Action., a new awareness campaign focused on increasing people’s understanding... More...>>
11/28/20167:00AMBWFDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) Seeking Approval for KEYTRUDA® (pe...
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) accepted for review the supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of previously treated patients... More...>>
11/28/201612:40AMDJNAmazon Broadens Cloud Services as Big Companies Sign On
SEATTLE–Amazon.com Inc.'s first cloud-computing conference in 2011 was a curiosity. Many of its 6,000 attendees worked for startups that had chosen to buy access to processing power and data storage via the web from Amazon Web Services rather than own and maintain their own data centers. With the fifth Amazon... More...>>
11/28/201612:30AMDJNAmazon Broadens Cloud Services as Big Companies Sign On
By Jay Greene SEATTLE-- Amazon.com Inc.'s first cloud-computing conference in 2011 was a curiosity. Many of its 6,000 attendees worked for startups that had chosen to buy access to processing power and data storage via the web from Amazon Web Services rather than own and maintain their own data centers. With the fifth... More...>>
11/24/20169:29AMDJNHouse GOP Business-Tax Plan Upends U.S. Policy, Bares Corporate Fault Lines
By Richard Rubin WASHINGTON -- Fault lines inside the corporate world are emerging over a proposed rewrite of the U.S. tax code, pitting importers against exporters. At the heart of the fight is a Republican plan in Congress that would impose corporate taxes on imports while eliminating them from exports, a move that would... More...>>
11/23/201610:02AMDJNEli Lilly Alzheimer's Drug Fails Late-Stage Trial -- 3rd Update
By Peter Loftus An experimental Eli Lilly & Co. drug failed to significantly help Alzheimer's disease patients in a closely watched clinical trial, dealing another blow to the pharmaceutical industry's long quest to find a better treatment for the condition. The disappointing outcome also may revive doubts... More...>>
11/23/20169:44AMDJNEli Lilly's Late Stage Alzheimer's Trial Fails To Achieve Goal -- 2nd Update
By Peter Loftus An experimental Eli Lilly & Co. drug failed to significantly help Alzheimer's disease patients in a closely watched clinical trial, dealing another blow to the pharmaceutical industry's long quest to find a better treatment for the condition. The disappointing outcome also may revive doubts... More...>>
11/22/20161:22PMBWMerck Announces Increased Quarterly Dividend
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has increased the company’s quarterly dividend to $0.47 per outstanding share of the company’s common stock, up $0.01 from $0.46 per outstanding share paid last quarter. Payment will be made on Jan. 9... More...>>
11/22/20167:00AMBWNew KEYTRUDA® (pembrolizumab) Data in Blood Cancers to be Presented at 58th Annual Meeting of the American Society of Hemato...
Updated Findings with Longer Follow-Up in Classical Hodgkin Lymphoma to be Featured in Oral Presentations Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data regarding the investigational use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with... More...>>
11/18/20161:51PMDJNSanofi to Stop Production of Bladder-Cancer Drug BCG -- Update
By Peter Loftus Sanofi SA plans to stop producing a bladder-cancer treatment that was in short supply for several years, saying it hasn't been able to restore full production at a Toronto manufacturing plant that had contamination problems. Sanofi said in a statement Friday it will cease production of its version... More...>>
11/18/201611:23AMDJNSanofi to Stop Production of Bladder-Cancer Drug BCG
By Peter Loftus Sanofi SA plans to stop producing a bladder-cancer treatment that was in short supply for several years, saying it hasn't been able to restore full production at a Toronto manufacturing plant that had contamination problems. Sanofi said in a statement Friday it will cease production of its version... More...>>
11/17/20169:00AMBWMerck Foundation Announces $10 Million Initiative to Improve Access to High-Quality Diabetes Care in Vulnerable & Underserved...
Non-Profit Organizations Invited to Apply for Grants to Improve Access to Diabetes Care The Merck Foundation (Foundation) announced today the launch of a new initiative, Bridging the Gap: Reducing Disparities in Diabetes Care (Bridging the Gap), to improve access to high-quality diabetes care and reduce health disparities... More...>>
11/15/20163:30AMDJNMerck Raises Guidance
FRANKFURT—German pharmaceuticals and chemicals company Merck KGaA on Tuesday reported a near 26% rise in profit for the third quarter and raised its guidance for the full year because of growth at the life science and health-care businesses. Net profit for the period ended Sept. 30 was €457 million ($491.4... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:34 V:us D:20161206 19:56:06